 ThirdAge | FDA Approves Denosumab for Patients With Cancer Medscape as a treatment to increase bone mass in men at high risk for fracture who are receiving androgen deprivation therapy for nonmetastatic prostate cancer. "Bone loss and fractures are recognized adverse effects of hormone ablation therapies, … FDA clears Amgen bone drug for cancer patients FDA Okays Denosumab for Cancer-Induced Bone Loss FDA approves 2 new indications for denosumab |
FDA Approves Denosumab for Patients With Cancer – Medscape
September 19, 2011
